Valganciclovir Hydrochloride Solid Dosage Form Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Valganciclovir hydrochloride liquid dosage forms exhibit short-term instability, making them unsuitable for pediatric use and patients requiring flexible dosages, necessitating the development of stable solid and liquid pharmaceutical dosage forms for oral administration.
Innovation Solution
A solid pharmaceutical dosage form comprising a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid to stabilize it in water, with an optional non-hygroscopic bulking agent, and a liquid form constituted from this solid with water, ensuring stability and flexibility in dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a liquid dosage form of valganciclovir hydrochloride is developed for pediatric use and flexible dosing, then ease of operation and adaptability are improved, but stability deteriorates due to short-term instability
Solution Approach 1:
The invention segments the liquid dosage form into two separate components: a stable solid powder formulation containing valganciclovir hydrochloride and excipients, and a liquid vehicle for reconstitution. This segmentation allows the solid component to maintain stability during storage while the liquid form provides ease of administration when prepared, resolving the contradiction between stability and ease of operation.
Solution Approach 2:
The solid powder formulation is prepared in advance with all necessary excipients and stabilizing agents incorporated. This preliminary action ensures that the active ingredient is protected in a stable solid state before use, while the liquid vehicle is prepared separately for reconstitution at the time of administration, combining stability during storage with ease of use when needed.
2Adaptability or versatility
If a liquid dosage form is used to provide flexible dosing levels, then adaptability is improved, but manufacturing precision and stability worsen
Solution Approach 1:
By segmenting the dosage form into a solid powder concentrate and a liquid vehicle, the invention enables precise manufacturing of the stable solid component containing the exact drug concentration. The flexibility in dosing is achieved through variable volumes of reconstitution rather than varying concentrations during manufacturing, thus maintaining manufacturing precision while providing dosage adaptability.
Solution Approach 2:
The invention changes the parameter being varied from concentration (which would require complex manufacturing adjustments) to volume (which is simple to control). The solid powder contains a fixed, precisely manufactured concentration, and dosage flexibility is achieved by varying the volume of liquid vehicle added during reconstitution, thereby maintaining manufacturing precision while providing adaptability.
3Reliability
If stability is improved by using solid dosage form, then reliability is improved, but ease of operation worsens due to constitution requirement
Solution Approach 1:
The liquid vehicle acts as an intermediary that facilitates the transition from the stable solid powder form to the administrable liquid form. The vehicle is designed to be simple to mix and contains no complex stabilizing agents, making the reconstitution process straightforward while maintaining the stability benefits of the solid formulation during storage.
4Duration of action of stationary object
If a stable formulation is developed for long-term storage, then shelf life is improved, but device complexity increases due to two-component system
Solution Approach 1:
The invention extracts the water and labile excipients from the final dosage form, retaining only the stable solid components in the powder formulation. This extraction of the unstable elements (water and certain excipients) allows for long-term storage stability, while the complete formulation including liquid vehicle is relatively simple and does not require complex stabilizing systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable valganciclovir hydrochloride formulation with improved manufacturability and shelf life, allowing for a wide range of dosage levels, particularly beneficial for pediatric patients and those needing flexible dosing, while maintaining therapeutic effectiveness.
Implementation Method 1
a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water
Data Source
AI summary
The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.